Oximal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oximal

Property Description
Active ingredient Meloxicam
Form Tablet, Capsule, Oral Suspension, IV Solution
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relief of pain, inflammation, and fever
Origin Synthetic (Oxicam Derivative)

Oximal: Definition and Core Pharmacological Type

Oximal is a prescription medicinal product whose active component, Meloxicam (INN), classifies it as a Nonsteroidal Anti-inflammatory Drug (NSAID). Meloxicam is a synthetic chemical entity derived from the oxicam chemical group and is specifically subclassified as a preferential Cyclooxygenase-2 (COX-2) inhibitor. This pharmacological approach is noted for its targeted action compared to non-selective NSAIDs.

The preparation is consistently a single active ingredient product, containing only Meloxicam, and is available in multiple dosage forms, including tablets, capsules, an oral suspension, and a specialized solution for intravenous injection. This diversity in forms facilitates both oral and intravenous administration, distinguishing it by allowing for flexible management, such as transitioning a patient from acute injectable therapy to sustained oral management.

What is the General Purpose of Oximal?

The general purpose of Oximal is to provide symptomatic relief through its core physiological actionsanalgesic (pain-relieving), anti-inflammatory (swelling-reducing), and antipyretic (fever-reducing) effects. The mechanism of preferential COX-2 inhibition underpins this function, primarily working to decrease the synthesis of prostaglandins, which are key chemical substances that mediate pain and inflammation signals in the body. For instance, the drug is commonly used to ease the chronic discomfort and stiffness associated with conditions like rheumatic arthritis. Meloxicam is utilized to ease pain and reduce inflammation by inhibiting the inflammatory cascade.

Regulatory References

  1. National Institutes of Health (NIH) LiverTox review

What side effects are possible with Oximal?

Possible Side Effects and Safety Information

The official safety profile of Oximal (Meloxicam) is structured by regulatory authorities to classify potential adverse reactions based on their frequency and the body system affected. The most frequently documented adverse events are typically classified as Common and involve Gastrointestinal disorders, which may present as dyspepsia, nausea, vomiting, abdominal pain, or diarrhea. Other common reactions involve the nervous system, such as headache, and general conditions like peripheral edema.

Serious Adverse Reactions and Systemic Risks

Official labeling mandates specific warnings regarding Serious Adverse Reactions. These include the risk of potentially life-threatening Cardiovascular Thrombotic Events, such as myocardial infarction and stroke. Furthermore, the medicine is associated with serious Gastrointestinal (GI) Events, including ulceration, bleeding, and perforation, as well as severe dermatological reactions like Stevens-Johnson syndrome.

The risk of both serious cardiovascular and serious GI events is explicitly documented to increase with the duration of use. Safety notes also indicate that Older Adults are officially considered to be at a greater risk for these serious adverse events.

Regulatory Safety Constraints

Safety limitations include Contraindications against its use in the peri-operative period of Coronary Artery Bypass Graft (CABG) surgery, and in patients with known severe uncontrolled heart failure. High-level safety notes also address potential consequences of interactions, such as an increased risk of bleeding when used concurrently with certain anticoagulants, and the possibility of diminished effectiveness of anti-hypertensive medications.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented overdose profile for Oximal (Meloxicam), strictly based on government regulatory information.


Documented Overdose Manifestations

Acute overdose may initially present with non-specific, generally reversible signs such as Lethargy, Drowsiness, Nausea, Vomiting, and Epigastric pain. Severe, life-threatening outcomes documented in regulatory labeling include Acute renal failure, Cardiovascular collapse, Respiratory depression, Coma, and Gastrointestinal bleeding.

Required Emergency Actions

Immediate medical attention must be sought for patients who have taken a substantial overdose or exhibit any severely symptomatic presentation, particularly those involving organ system compromise. Official guidance mandates management with Symptomatic and supportive care as no specific antidote is known for Meloxicam overdose. Procedures such as the administration of Activated charcoal and Cholestyramine are documented to assist in accelerating drug clearance. Hospital monitoring and observation are required for substantial exposures or the development of severe complications.

Therapeutic Uses of Oximal

What Oximal Treats: Main Uses and Benefits

Oximal is commonly used to help manage symptoms related to inflammatory or irritative states. It is relevant across conditions characterized by periods of heightened symptoms to help manage pain, swelling, tenderness, and joint stiffness.

This medication is typically applied across therapeutic domains where additional symptomatic support is needed for long-term conditions like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis. It is applied in clinical settings that involve acute or unstable symptom patterns, such as moderate-to-severe pain and associated swelling.

It is relevant for managing symptom clusters that create noticeable physiological strain, supporting the patient during episodes of heightened discomfort. It is also considered relevant for pediatric patients with Juvenile Rheumatoid Arthritis (JRA).

“Oximal is primarily used to provide supportive relief during difficult episodes, assisting with managing symptoms that interfere with routine activities and general comfort.”

Quick Fact: Relief for Inflammation & Pain
Oximal is commonly used in contexts involving chronic inflammation or acute tissue discomfort, supporting the management of symptoms related to physical discomfort and functional stability.

Regulatory References

  1. NIH MedlinePlus overview of Meloxicam

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Oximal

Oximal (a representative nonsteroidal anti-inflammatory drug, or NSAID) is prohibited or restricted for use in specific populations as defined by regulatory bodies (e.g., FDA, EMA).

Category Official Regulatory Status
Populations for whom use is contraindicated: Patients with known hypersensitivity to Oximal or other NSAIDs, history of aspirin-sensitive asthma, or who are in the setting of coronary artery bypass graft (CABG) surgery. Also patients with active gastrointestinal bleeding or ulceration.
Age-related eligibility rules: Generally approved for adults (typically ge 18 years of age). For Juvenile Rheumatoid Arthritis (JRA), use is established for pediatric patients ge 2 years of age in specific formulations. Older adults require careful monitoring due to higher risk.
Pregnancy and lactation eligibility status: Avoid use starting at 20 weeks gestation due to risk of fetal kidney problems, and prohibited from 30 weeks gestation onward due to risk of premature closure of the fetal ductus arteriosus. Use is not recommended in women who are breastfeeding.
Condition-specific eligibility rules: Avoid use in patients with advanced renal disease or severe heart failure unless benefits outweigh risk. Patients on hemodialysis require a maximum daily dose restriction as documented in the label.

These official statements delineate who is absolutely excluded and who requires conditional use based on organ function, medical history, and reproductive status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Oximal (Meloxicam) describes several clinically significant interaction patterns across multiple drug categories. The combination with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or analgesic doses of Aspirin is not generally recommended due to an increased risk of serious gastrointestinal events. Meloxicam is also contraindicated for the treatment of pain right before or after Coronary Artery Bypass Graft (CABG) surgery, a required regulatory restriction.

Pharmacodynamic and Clearance Interactions

Co-administration with Anticoagulants (e.g., Warfarin) and antiplatelet agents increases the risk of bleeding complications. Similarly, combining Oximal with SSRIs or SNRIs is associated with an elevated risk of gastrointestinal bleeding. A documented interaction exists with ACE Inhibitors, ARBs, and Diuretics, which can diminish their antihypertensive or diuretic effects and increase the risk of renal function deterioration, especially in the elderly or volume-depleted patients.

Meloxicam also affects the exposure of certain medicines. Co-administration increases the plasma concentration of Lithium and Methotrexate, leading to a potential risk of toxicity. Conversely, administration of Cholestyramine accelerates the clearance of Meloxicam, resulting in a documented 50% decrease in the drug's Area Under the Curve (AUC). Lastly, the oral suspension formulation must not be combined with Sodium Polystyrene Sulfonate due to the risk of intestinal necrosis.

Mechanism of Action

Oximal (Meloxicam) functions as a non-steroidal anti-inflammatory drug (NSAID) with preferential inhibitory activity directed at cyclooxygenase-2 (COX-2), a biological target predominantly inducible at sites of cellular activation.

. This interaction is a type of noncompetitive enzyme inhibition, where the drug molecule occupies a binding site within the cyclooxygenase enzyme.

By inhibiting COX-2, Oximal sterically and electronically prevents the initial enzymatic cascade: the conversion of arachidonic acid into unstable intermediates. This blockage consequently suppresses the intracellular synthesis of various prostaglandins and thromboxanes.

Downstream consequences include a reduction in the local concentrations of pro-inflammatory lipid mediators. System-level physiological modulation involves diminished peripheral and central sensitization of nociceptors and reduced pyretic and hyperemic responses, fundamentally modulating the local tissue response to various stimuli by lowering the signaling intensity of prostanoids.

Dosage and Administration Information

How to Use Oximal

Oximal (Meloxicam) is used according to strict, officially defined protocols that determine the route, dosage, frequency, and duration of administration. The guiding principle for all uses is to administer the lowest effective dose for the shortest duration necessary.


Administration Routes and Standard Regimens

Oximal is approved for both oral administration (tablets, capsules, and oral suspension) and intravenous (IV) injection. The standard frequency for all approved regimens is once daily.

Administration Route Standard Adult Dose Maximum Adult Dose Key Procedural Note
Oral (Tablet/Suspension) 7.5 mg once daily 15 mg once daily May be taken without regard to meals
Intravenous (IV) Injection 30 mg once daily 30 mg once daily Administered as a bolus over 15 seconds in a clinical setting

Population-Specific Use and Preparation

Official instructions include specific modifications for certain populations. Patients undergoing hemodialysis must limit their daily oral dose to a maximum of 7.5 mg. For pediatric patients with Juvenile Rheumatoid Arthritis (JRA), the dose is calculated on a weight-based scale (0.125 mg/kg once daily, not to exceed 7.5 mg).

For preparation, the oral suspension must be shaken gently prior to use to ensure accurate dosing. Furthermore, certain oral capsule forms are not interchangeable with the oral tablet/suspension forms, due to differences in systemic exposure.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Mechanism of Action and Initial Research

The compound is being examined in studies involving cholesterol by influencing specific metabolic pathways. This mechanism has been the focus of study to understand cellular processes involved. Early-stage research has explored findings related to participants across various therapeutic areas.

Studies investigated whether it could influence factors associated with chronic conditions. Other research has assessed factors related to timing in acute case studies.

Clinical Trials and Key Findings

Studies reported a change in disease markers over time in participants involved in phase II trials. The primary focus of these trials was to assess tolerability and initial observation.

A. Combination Therapy Studies

Clinical investigations compared the combination approach to single-agent treatment in patients with severe symptoms. Researchers evaluated different approaches to taking the medication to identify different dosing schedules.

B. Safety and Tolerability

Research has examined the safety profile across different adult populations, with adverse events being monitored closely. Reports detailing the frequency and severity of side effects are available in the public trial registries. Consulting a healthcare provider is generally recommended for context and interpretation.


Conclusion of Evidence

Current evidence is focused primarily on preliminary findings and safety data. It is important to note that definitive, large-scale studies are still ongoing. Decisions regarding clinical use or suitability should be made only in consultation with a qualified healthcare professional.

Key Studies & References

  1. Section 4.8: Undesirable effects guidance (European Medicines Agency) (Relevant to reporting frequency and severity of side effects in trial registries)

Frequently Asked Questions (FAQ)

Common questions about Oximal (FAQ)


Q: Does Oximal have any known black box warnings?

Yes, the official prescribing information includes a Boxed Warning, which is the strongest warning regulatory bodies can require.

This warning alerts users to the potential for serious cardiovascular thrombotic events (like heart attack and stroke) and severe gastrointestinal adverse events (like bleeding, ulceration, or perforation).


Q: Is Oximal considered a long-term medication?

Oximal has approved uses for chronic conditions, such as certain types of arthritis.

However, official regulatory warnings highlight that the risk of serious cardiovascular and gastrointestinal adverse events, such as heart attack, stroke, or bleeding, may increase with the duration of use.


Q: How long does the effect of a single dose of Oximal last?

The duration of a single dose of Oximal is related to its elimination half-life, which is the time it takes for half of the medicine to be cleared from the plasma.

According to regulatory documents, the half-life of Oximal is approximately 20 hours. This half-life property aligns with the drug’s approved once-daily dosing regimen.


Q: How long after stopping Oximal will it be completely out of my system?

The time it takes for Oximal to be fully cleared is determined by its half-life, which is about 20 hours.

Generally, a medication is considered to be mostly cleared from the system after a period equal to four to five half-lives. This process varies slightly from person to person.


Q: Is Oximal chemically related to any other well-known drugs?

Official drug labeling states that Oximal's active ingredient, Meloxicam, belongs to the family of Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Chemically, it is classified as a synthetic derivative of the oxicam group of compounds.


Q: Is Oximal addictive or habit-forming?

Oximal is officially classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

It is classified as a non-controlled substance and is not generally associated with the potential for physical addiction or habit formation.


Q: Is there a generic version of Oximal available?

Yes, the active component of Oximal, known by the international non-proprietary name (INN) Meloxicam, is widely available as a generic medication.


Q: Can I take Oximal if I have high blood pressure?

Official warnings advise caution for individuals with existing high blood pressure.

Regulatory information states that Oximal can potentially increase blood pressure and may reduce the effectiveness of some blood pressure medications. Regulatory warnings suggest that blood pressure should be closely monitored in patients with hypertension.


Q: Is Oximal safe for people who have liver problems?

Official warnings address the potential for hepatotoxicity (liver damage).

Patients with hepatic impairment should be monitored, and official guidance indicates that its use is often restricted or carefully considered for individuals with severe liver disease.


Q: Are there restrictions on driving or operating machinery while on Oximal?

Yes, official patient information advises caution.

Regulatory documents caution that patients should ensure they know how the medication affects them, as adverse effects may include dizziness, drowsiness, or blurred vision, which could impair the ability to drive or operate complex machinery safely.


Q: Does alcohol make Oximal less effective?

Regulatory sources do not indicate that alcohol reduces the effectiveness of Oximal.

The official label includes a warning against combining Oximal with alcohol because it significantly increases the risk of serious gastrointestinal bleeding and irritation.


Q: Are there any specific foods to avoid while taking Oximal?

Oximal tablets can generally be taken without regard to meals.

However, an interaction is documented with grapefruit juice, which official sources indicate may increase the concentration of the medicine in the body.


Q: What should I do if I miss a scheduled dose of Oximal?

Patient information guides provide general directions, such as taking a missed dose as soon as it is recognized.

If it is almost time for the next scheduled dose, the product information states the importance of skipping the missed dose and avoiding taking double or extra doses.


Q: Are there any documented cases of Oximal overdose?

The patient information includes a section describing the symptoms of potential overdose.

These documented signs may include seizures, excessive drowsiness, severe nausea/vomiting, and serious gastrointestinal effects.


Q: Why do some people experience better results with Oximal than others?

Official regulatory information indicates that the body's processing of Oximal can vary due to differences in the CYP2C9 enzyme, which is responsible for breaking down the drug.

These genetic variations can affect how high the medicine concentration gets in the blood and how long it stays there, leading to differences in individual response.


Q: Can Oximal cause weight gain?

While not listed as a common reaction, official safety information indicates that rapid weight gain is a possible, though less common, adverse effect.

This potential change is often associated with the documented risk of swelling or fluid retention (edema).


Q: Is it common to feel tired when taking Oximal?

Regulatory safety documents list both tiredness (fatigue) and drowsiness as potential adverse effects.

These are typically noted under the nervous system or general disorders section of the official product information.


Q: Does Oximal affect sleep?

Official safety data lists potential nervous system adverse effects that relate to sleep.

These include reports of insomnia (difficulty falling or staying asleep) and, in some instances, abnormal dreaming.


Q: Is it true that Oximal can cause changes in mood?

Yes, official safety profiles list certain changes in mood as potential adverse effects.

These nervous system reactions include reports of feelings of anxiety and mild depression.


Q: How does Oximal affect my ability to concentrate?

Official safety data lists potential central nervous system effects.

These adverse reactions may include reports of trouble concentrating and general confusion.


How should Oximal be stored and disposed of?

How to Store and Dispose of Oximal

Official regulatory guidelines define the mandatory storage and disposal requirements for Oximal to ensure product stability and safety.

Storing Oximal

Requirement Official Instruction
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the medicine in its original container, protected from light and excessive moisture.
Safety Always keep Oximal secured, out of the sight and reach of children.

Disposing of Oximal

To dispose of unused or expired Oximal, regulatory agencies instruct using an authorized drug take-back program. If a take-back option is unavailable, the medication must be mixed with an unappealing substance, sealed in a bag or container, and discarded in the household trash. Do not flush the medicine down a toilet or drain unless specifically instructed by the official label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oximal found in:

A-Z Index: